Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by BeiGene, Ltd.

< Previous 1 2 3 Next >
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Reports Third Quarter 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Inclusion in FTSE Russell Indices
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research on August 25, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Reports Second Quarter 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.